Sound biological rationale exists for the co-administration of docetaxel plus abiraterone and prednisone as a treatment regimens for patients with metastatic castration-resistant prostate cancer (mCRPC). Newly published results from a phase Ib dose-escalation study in three cohorts of men with chemotherapy naïve mCRPC suggest a recommended phase II dose of 75 mg/m² docetaxel, 1,000 mg abiraterone, plus 10 mg prednisone. Investigators reported a high rate of serum PSA decline; however, the efficacy of this approach will require further investiation in later-phase clinical trials.
References
Tagawa, S. T. et al. Phase 1b Study of abiraterone acetate plus prednisone and docetaxel in patients with metastatic castration-resistant prostate cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.01.028 (2016)
Rights and permissions
About this article
Cite this article
Sidaway, P. Triple combination therapy tested in mCRPC. Nat Rev Urol 13, 182 (2016). https://doi.org/10.1038/nrurol.2016.40
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.40